A Case of Typical Hemolytic Uremic Syndrome in an Adult.

Ramez Kouzy,Fares Sukhon,Rasha Alawieh,Sally Temraz

doi:10.7759/cureus.3289

Abstract

Typical hemolytic uremic syndrome (HUS) in adults is an uncommon clinical occurrence and has been rarely reported in the literature. Typical HUS is mainly caused by Shiga toxin-producing Escherichia coli (STEC) and is typically a pediatric disease. Worldwide outbreaks have been reported, one of the largest and most recent being in Germany. We are reporting a case of a 55-year-old male who presented with acute diarrhea. His laboratory parameters were suggestive of HUS and molecular testing was positive for STEC in stools. The patient received supportive therapy, and he recovered clinically with an improvement in his laboratory parameters. We hereby highlight the importance of timely diagnosis of typical HUS in guiding management and avoiding unnecessary testing and treatment. The mainstay of therapy is aggressive and prompt intravenous hydration to help alleviate the acute kidney injury and improve the clinical outcomes.

Highlights

Hemolytic uremic syndrome (HUS) belongs to a wide variety of diseases called thrombotic microangiopathies, which primarily refers to pathologies due to vascular damage [1].Received 08/28/2018 Review began 09/04/2018 Review ended 09/08/2018 Published 09/11/2018Hemolytic uremic syndrome in children has been widely recognized to be caused by Shiga toxin-producing Escherichia coli (STEC) such as E. coli O157:H7; cases of Shiga toxinproducing Escherichia coli (STEC)-hemolytic uremic syndrome (HUS) are rarely reported in adults worldwide [2]
Typical HUS is mainly caused by Shiga toxinproducing Escherichia coli (STEC) and is typically a pediatric disease
We are reporting a case of a 55-year-old male who presented with acute diarrhea. His laboratory parameters were suggestive of HUS and molecular testing was positive for STEC in stools

Summary

A Case of Typical Hemolytic Uremic Syndrome in an Adult

1. Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston , USA 2. American University of Beirut Medical Center, Beirut, LBN 3. Hematology & Oncology, American University of Beirut Medical, Beirut, LBN

Introduction

Discussion

Conclusions

Disclosures

Canpolat N